Patents by Inventor Weidong Feng
Weidong Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951778Abstract: A sound absorber is configured as a rectangular hexahedral box and forms a porous double-layer Helmholtz resonance sound absorbing structure, at the same time, the sound absorber in the form of a box forms a structural resonance sound absorbing device itself, and the first-order natural mode frequency of the device is identical to that of a wheel air chamber. When the box-type sound absorbing structure is assembled in a wheel, double functions of absorbing acoustic resonance of the wheel air chamber under the organic combination of Helmholtz resonance sound absorption and structural resonance sound absorption can be realized.Type: GrantFiled: January 19, 2020Date of Patent: April 9, 2024Assignee: CITIC Dicastal Co., LTDInventors: Shiwen Xu, Mingbo Chen, Minglei Li, Shaobing Huang, Tiefeng Hu, Shuwei Feng, Dadong Wang, Weidong Liu
-
Patent number: 9889123Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).Type: GrantFiled: January 25, 2017Date of Patent: February 13, 2018Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventor: Weidong Feng
-
Publication number: 20170128427Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).Type: ApplicationFiled: January 25, 2017Publication date: May 11, 2017Inventor: Weidong FENG
-
Patent number: 9573900Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).Type: GrantFiled: July 16, 2013Date of Patent: February 21, 2017Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventor: Weidong Feng
-
Publication number: 20150266823Abstract: The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1?,1?,1?-trideutero-methyl)picolinamide or its salt, namely, polymorphs of the compound as shown in formula (I) or its salt. The polymorphs are suited for preparing the pharmaceutical composition used for inhibiting phosphokinase (such as raf kinases).Type: ApplicationFiled: July 16, 2013Publication date: September 24, 2015Inventor: Weidong Feng
-
Patent number: 9078933Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.Type: GrantFiled: January 14, 2014Date of Patent: July 14, 2015Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Patent number: 9072796Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.Type: GrantFiled: November 27, 2013Date of Patent: July 7, 2015Assignee: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Publication number: 20150175545Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.Type: ApplicationFiled: March 4, 2015Publication date: June 25, 2015Inventors: Weidong Feng, Xiaoyong GAO, Xiaojun DAI
-
Patent number: 8759531Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.Type: GrantFiled: March 17, 2011Date of Patent: June 24, 2014Assignee: Suzhou Zelgen Biopharmaccceutical Co., Ltd.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Patent number: 8748666Abstract: Preparation methods of methyl-d3-amine and salts thereof are provided, which contain the following steps: (i) nitromethane is subjected to react with deuterium oxide in the present of bases and phase-transfer catalysts to form nitromethane-d3, which is subsequently subjected to reduction in an inert solvent to form methyl-d3-amine, and optionally, methyl-d3-amine reacts subsequently with acids to form salts of methyl-d3-amine; or (ii) N-(1,1,1-trideuteriomethyl)phthalimide is subjected to react with acids to form salts of methyl-d3-amine. The present methods are easy, high efficient, and low cost.Type: GrantFiled: March 17, 2011Date of Patent: June 10, 2014Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Xiaoyong Gao, Weidong Feng, Xiaojun Dai
-
Publication number: 20140128612Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Weidong FENG, Xiaoyong GAO, Xiaojun DAI
-
Publication number: 20140088311Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.Inventors: Weidong FENG, Xiaoyong GAO, Xiaojun DAI
-
Patent number: 8669369Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.Type: GrantFiled: March 17, 2011Date of Patent: March 11, 2014Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Patent number: 8618306Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.Type: GrantFiled: March 17, 2011Date of Patent: December 31, 2013Assignee: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Publication number: 20130060044Abstract: Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.Type: ApplicationFiled: March 17, 2011Publication date: March 7, 2013Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Publication number: 20130060043Abstract: A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.Type: ApplicationFiled: March 17, 2011Publication date: March 7, 2013Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTDInventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Publication number: 20130035492Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenye-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.Type: ApplicationFiled: March 17, 2011Publication date: February 7, 2013Applicant: SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD.Inventors: Weidong Feng, Xiaoyong Gao, Xiaojun Dai
-
Publication number: 20130018209Abstract: Preparation methods of methyl-d3-amine and salts thereof are provided, which contain the following steps: (i) nitromethane is subjected to react with deuterium oxide in the present of bases and phase-transfer catalysts to form nitromethane-d3, which is subsequently subjected to reduction in an inert solvent to form methyl-d3-amine, and optionally, methyl-d3-amine reacts subsequently with acids to form salts of methyl-d3-amine; or (ii) N-(1,1,1-trideuteriomethyl)phthalimide is subjected to react with acids to form salts of methyl-d3-amine. The present methods are easy, high efficient, and low cost.Type: ApplicationFiled: March 17, 2011Publication date: January 17, 2013Applicant: Suzhou Zelgen Biopharmaceutical Co., Ltd.Inventors: Xiaoyong Gao, Weidong Feng, Xiaojun Dai